North America Blood Screening Market Size, Share & Forecast (2020-2035)
The North America Blood Screening Market is witnessing significant growth propelled by the heightened focus on blood safety, technological innovations in diagnostics, and a consistently high volume of blood transfusions and donations. The market landscape is increasingly shaped by advanced molecular assay methods, regulatory compliance, and the growing adoption of next-generation sequencing for early infection detection. With the presence of leading manufacturers and ongoing R&D activity, the region dominates the global blood screening sector, and this trajectory is sustained by robust investments from both private and public entities. By 2025, the market growth is expected to continue with rising awareness for disease prevention and stringent quality standards in healthcare. Key sectors driving demand include hospitals, blood banks, and diagnostic centers, supported by major industry players advancing automation and molecular diagnostics.
Latest Market Dynamics
Key Drivers
- Technological advancements in blood screening, such as the deployment of automated nucleic acid testing (NAT) platforms, are accelerating early detection of infectious diseases. In 2024, Abbott Laboratories expanded its Alinity m system across North America to enhance blood safety and reduce contamination risks.
- Rising prevalence of infectious diseases and increasing demand for blood transfusions are driving screening activities. In 2024, Grifols S.A. reported growth in systems designed for large hospital networks and blood banks to efficiently manage rising testing volumes.
Key Trends
- Integration of artificial intelligence and digital health tools to streamline laboratory workflows is a key trend. In 2024, Bio-Rad Laboratories introduced AI-powered platforms that optimize results interpretation and process management in blood testing.
- Growing adoption of multiplex assays and next-generation sequencing (NGS) for multi-pathogen detection is rising. Roche, in June 2024, launched enhanced NGS panels for simultaneous screening of various transfusion-transmissible infections.
Key Opportunities
- Expansion into point-of-care testing with portable rapid test devices creates new market avenues. Thermo Fisher Scientific, in July 2024, launched portable NAT systems targeting rural clinics and emergency transfusion units.
- Collaborations with public health bodies to implement mass blood screening during outbreaks provide growth prospects. Siemens Healthineers partnered with Canadian authorities in June 2024 to deploy emergency infection surveillance kits.
Key Challenges
- Regulatory complexities and prolonged approval timelines for new technologies remain a challenge. Companies such as BD (Becton, Dickinson and Company) cited delays in regional rollouts after regulatory protocol changes in 2024.
- Shortages of skilled personnel for operating high-end diagnostic instruments continue to hinder test throughput, as reported by Ortho Clinical Diagnostics in their 2024 operational review.
Key Restraints
- High capital investment and running costs for advanced automated platforms restrict adoption among smaller institutions. Many diagnostic centers cited equipment purchase costs as a barrier in 2024.
- Stringent regulatory compliance and quality validation requirements can slow market entry. BioMérieux SA noted extended certification cycles for new assays in their 2024 market update.
Market Share by Type, 2025
In 2025, Reagent & Kits are expected to dominate the North America Blood Screening Market by type, representing the largest portion of usage due to their critical role in routine testing processes. Instruments, which are essential for automating and streamlining laboratory workflow, are projected to be the second-largest segment. Software & Services cover solutions for data management and result analysis, reflecting the growing focus on digitalization in diagnostics. This distribution highlights a balanced adoption of consumables and technology, driven by ongoing efforts to improve efficiency, accuracy, and compliance in blood screening.
Market Share by Application, 2025
Blood transfusion application constitutes the largest market share in the North America Blood Screening Market for 2025, driven by the region’s high demand for safe and efficient transfusion services. Infection detection remains the second-largest application, reflecting growing necessity to prevent transmissible diseases through rigorous screening protocols. Disease prevention and control account for a significant segment, highlighting increased awareness and initiatives in public health safety. The application mix is a clear indicator of the region’s strong focus on quality healthcare delivery and infection control across a range of medical and research settings.
Market Revenue by Year (2020–2035)
The North America Blood Screening Market is projected to grow steadily from 2020 to 2035, with revenue increasing from 2,720 million USD in 2020 to approximately 4,800 million USD by 2035. This upward trend is supported by the continual introduction of advanced screening technologies and rising awareness about blood-borne infections. Market expansion is particularly marked in the post-pandemic years, reflecting renewed investments in healthcare infrastructure and digital transformation in diagnostics. The robust CAGR throughout the period indicates sustainable demand growth and technological progress within the screening segment.
Year-on-Year Growth Rate (%) (2020–2035)
Year-on-year growth rates for the North America Blood Screening Market are projected to maintain a stable curve from 2020 to 2035. The market experienced a significant jump of 7.1% in 2021, boosted by a post-pandemic increase in blood donations and testing. Annual growth is forecasted to stabilize at around 5.5% through 2025–2030, gradually tapering to 4.2% by 2035 as the market matures and penetrates deeper into hospital and outpatient settings. Sustained investments and a steady stream of technological breakthroughs are expected to reinforce the market’s positive growth trajectory throughout the forecast period.
Market Share by Region, 2025
In 2025, the United States will continue to be the dominant region in the North America Blood Screening Market, accounting for the majority of the market share owing to its extensive healthcare infrastructure and high testing volume. Canada follows as the second-largest contributor, benefitting from increased investment in healthcare modernization and strong public health initiatives. Mexico, while smaller, is experiencing the fastest growth due to public health campaigns and improving access to advanced screening methods. This distribution underscores the disparity in healthcare capacity yet highlights the overall regional progress in ensuring safer blood supplies.
Market Share by Leading Players, 2025
Abbott Laboratories leads the North America Blood Screening Market in 2025 due to its diversified product offerings and rapid deployment of automated solutions. Grifols S.A. and F. Hoffmann-La Roche AG also command significant shares, with strong pipelines and strategic partnerships within healthcare institutions. Other notable contributors include Bio-Rad Laboratories and BD, while the remainder is shared among specialized and regional players. The competitive landscape is distinguished by intensive R&D, robust mergers & acquisitions, and rapid technological innovation, all serving to maintain market dynamism.
Market Share by Buyer Type, 2025
The highest proportion of blood screening market purchases in North America in 2025 is attributed to hospitals, reflecting their central role in patient care and transfusion services. Blood banks are responsible for the second-largest share, catering to both donation and storage needs, followed by diagnostic centers which have expanded their screening services with the latest molecular technologies. This segmentation highlights the broadening use of screening products across diversified healthcare settings, underpinned by an urgent focus on safety, efficiency, and regulatory compliance.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 3400 |
| Regions | United States, Canada, Mexico |
| Segments | Reagent & Kits, Instruments, Software & Services, Accessories, Consumables, Others; Blood Transfusion, Infection Detection, Disease Prevention & Control, Blood Donations, Research Application, Others |
| Players | Abbott Laboratories, Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Ortho Clinical Diagnostics, bioMérieux SA, DiaSorin S.p.A., PerkinElmer Inc., Enzo Biochem Inc., Trinity Biotech Plc, Merck KGaA |
Key Recent Developments
- June 2024: Abbott Laboratories announced the commercial release of the Alinity m Blood Screening System with AI integration to improve infectious disease detection accuracy.
- July 2024: Thermo Fisher Scientific launched its GeneSwitch Portable NAT system for rapid point-of-care blood testing in rural and emergency settings.
- June 2024: Siemens Healthineers began collaboration with Public Health Agency of Canada to deploy blood screening kits for infectious disease outbreak response.
- August 2024: Roche introduced updated NGS panels for faster, multi-pathogen blood screening in high-throughput labs across North America.
- July 2024: Grifols S.A. expanded its blood bank automation suite with scalable software for large institutional networks in the United States and Canada.
